Related Experiment Videos
Aborted leiomyosarcoma after treatment with leuprolide acetate
A F Mesia1, F S Williams, Z Yan
1Department of Pathology, Kaplan Comprehensive Cancer Center, New York University Medical Center, New York 10016, USA.
Obstetrics and Gynecology
|October 9, 1998
Summary
Leuprolide acetate effectively shrinks uterine fibroids but can mask leiomyosarcoma. Misdiagnosis due to this treatment can delay critical care for uterine sarcoma patients.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Reproductive Endocrinology
Background:
- Leuprolide acetate is a gonadotropin-releasing hormone agonist used to manage uterine leiomyomata (fibroids).
- Its efficacy in reducing uterine size and fibroid volume is well-established in selected patients.
- Potential complications arise if administered to patients with unsuspected uterine malignancies.
Observation:
- A patient diagnosed with presumed leiomyomata received monthly leuprolide acetate injections.
- During the third month of treatment, the patient experienced increased bleeding, expulsion of the mass, urinary retention, and severe pain.
- These severe symptoms indicated a potential underlying malignancy, necessitating urgent surgical intervention.
Findings:
- Treatment with leuprolide acetate can obscure the diagnosis of leiomyosarcoma.
- Delayed diagnosis increases patient morbidity and negatively impacts treatment outcomes for uterine sarcoma.
- Histological examination revealed changes in the leiomyosarcoma similar to those observed in leuprolide acetate-treated leiomyomata.
Implications:
- Clinicians must maintain a high index of suspicion for leiomyosarcoma in patients presenting with atypical symptoms during GnRH agonist therapy.
- Early and accurate diagnosis of uterine malignancies is crucial for effective treatment and improved patient prognosis.
- Consideration of alternative diagnostic pathways is warranted when fibroid treatments yield unexpected or severe patient responses.